|
Burkitt Lymphoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
The results demonstrated that β-elemene effectively inhibited the growth and induced the apoptosis of Burkitt's lymphoma cells through upregulation of PUMA expression and modulating PUMA related apoptotic signaling pathway.
|
30119230 |
2018 |
|
Burkitt Lymphoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Surprisingly, neither PUMA upregulation in normal activated human B lymphocytes nor high levels of PUMA in Burkitt's lymphoma (BL) were associated with cell death.
|
26431330 |
2015 |
|
Burkitt Lymphoma
|
0.330 |
GeneticVariation
|
disease |
LHGDN |
Burkitt lymphoma cell lines phenocopy the primary tumors with respect to DNA methylation and diminished PUMA expression, which can be reactivated following inhibition of DNA methyltransferases.
|
18573879 |
2008 |
|
Burkitt Lymphoma
|
0.330 |
Biomarker
|
disease |
CTD_human |
Burkitt lymphoma cell lines phenocopy the primary tumors with respect to DNA methylation and diminished PUMA expression, which can be reactivated following inhibition of DNA methyltransferases.
|
18573879 |
2008 |
|
Burkitt Lymphoma
|
0.330 |
PosttranslationalModification
|
disease |
BEFREE |
Burkitt lymphoma cell lines phenocopy the primary tumors with respect to DNA methylation and diminished PUMA expression, which can be reactivated following inhibition of DNA methyltransferases.
|
18573879 |
2008 |
|
Hepatoma, Morris
|
0.300 |
Biomarker
|
disease |
CTD_human |
Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice.
|
28100771 |
2017 |
|
Hepatoma, Novikoff
|
0.300 |
Biomarker
|
disease |
CTD_human |
Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice.
|
28100771 |
2017 |
|
Liver Neoplasms, Experimental
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice.
|
28100771 |
2017 |
|
Experimental Hepatoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice.
|
28100771 |
2017 |
|
Brain Ischemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Potential role of PUMA in delayed death of hippocampal CA1 neurons after transient global cerebral ischemia.
|
19095966 |
2009 |
|
Cerebral Ischemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Potential role of PUMA in delayed death of hippocampal CA1 neurons after transient global cerebral ischemia.
|
19095966 |
2009 |
|
African Burkitt's lymphoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis.
|
18573879 |
2008 |
|
Burkitt Leukemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis.
|
18573879 |
2008 |
|
Esophageal Neoplasms
|
0.300 |
Therapeutic
|
group |
CTD_human |
Interestingly, Ad-PUMA was found to be more efficient than Ad-p53 in inhibiting cell growth and enhancing the chemosensitivity of esophageal cancer cell lines irrespective of the p53 status.
|
16481741 |
2006 |
|
Malignant neoplasm of esophagus
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Interestingly, Ad-PUMA was found to be more efficient than Ad-p53 in inhibiting cell growth and enhancing the chemosensitivity of esophageal cancer cell lines irrespective of the p53 status.
|
16481741 |
2006 |
|
Transient Ischemic Attack
|
0.210 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, TUNEL-positive CA1 pyramidal neurons were found at 5 days after TCI with increased expression levels of Bax, PUMA, and activated caspase-3.
|
31506563 |
2019 |
|
Transient Ischemic Attack
|
0.210 |
Biomarker
|
disease |
RGD |
Gene expression during ER stress-induced apoptosis in neurons: induction of the BH3-only protein Bbc3/PUMA and activation of the mitochondrial apoptosis pathway.
|
12913114 |
2003 |
|
Intermittent Claudication
|
0.200 |
Biomarker
|
phenotype |
RGD |
Over-expression of PUMA correlates with the apoptosis of spinal cord cells in rat neuropathic intermittent claudication model.
|
23658678 |
2013 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PUMA is a pro-apoptotic Bcl-2 family protein that can act as a tumor suppressor or oncogene in different cancers.In this issue, Kim et al. show that PUMA, independent of its apoptotic function, enforces glycolytic metabolism by inhibiting the transport of pyruvate into the mitochondria, promoting hepatocellular carcinoma.
|
30753820 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA.
|
31726940 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Structure-based pharmacophore modeling aided in the identification of PUMA inhibitors, structure based approach with high throughput screening for the development of Bcl-2 inhibitors, to derive the most relevant protein-protein interactions, anti mitotic agents; I-Kappa-B Kinase β (IKK- β) inhibitor, screening of new class of aromatase inhibitors that can be important targets in cancer therapy.
|
30207247 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PUMA is a pro-apoptotic Bcl-2 family protein that can act as a tumor suppressor or oncogene in different cancers.In this issue, Kim et al. show that PUMA, independent of its apoptotic function, enforces glycolytic metabolism by inhibiting the transport of pyruvate into the mitochondria, promoting hepatocellular carcinoma.
|
30753820 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA.
|
31726940 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Structure-based pharmacophore modeling aided in the identification of PUMA inhibitors, structure based approach with high throughput screening for the development of Bcl-2 inhibitors, to derive the most relevant protein-protein interactions, anti mitotic agents; I-Kappa-B Kinase β (IKK- β) inhibitor, screening of new class of aromatase inhibitors that can be important targets in cancer therapy.
|
30207247 |
2019 |